Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peanut SLIT for Tolerance in Children
NCT01373242Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jun 2011
- Primary completion
- Apr 2018
- Modality
- Transdermal Patches
- Countries
- 1
01
Overview
Phase 2, open-label trial of DBV712 Viaskin® in peanut allergy, sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Population Sensitization Threshold (ED05), Population Sensitization Threshold (ED10) and 1 more. Started Jun 2011; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT01373242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373242.